Laxiriva Neutral: Uses, Dosage & Side Effects

What Is Laxiriva Neutral and What Is It Used For?

Laxiriva Neutral belongs to a class of medications known as osmotic laxatives. The active ingredient, macrogol 3350 (also known internationally as polyethylene glycol 3350 or PEG 3350), is a high-molecular-weight linear polymer of ethylene oxide. Macrogol 3350 has been used extensively in clinical medicine for decades and is recognized by the World Health Organization (WHO), the European Medicines Agency (EMA), and the U.S. Food and Drug Administration (FDA) as a safe and effective treatment for constipation. The “Neutral” in the product name indicates that the formulation is unflavored, making it suitable for patients who prefer a taste-neutral preparation.

The mechanism of action of macrogol 3350 is elegantly simple and entirely physical rather than pharmacological. When dissolved in water and consumed orally, macrogol 3350 passes through the gastrointestinal tract without being absorbed or metabolized. As it travels through the intestines, it forms hydrogen bonds with water molecules, effectively retaining water in the intestinal lumen. This osmotic action increases the volume and water content of the stool, making it softer and easier to pass. The increased stool volume also gently distends the bowel wall, which triggers the natural peristaltic reflex – the rhythmic contractions of the intestinal muscles that move contents forward. Unlike stimulant laxatives (such as senna or bisacodyl), which directly irritate the nerve endings in the bowel wall to force contractions, macrogol 3350 works with the body’s own physiological mechanisms, resulting in a more comfortable and natural bowel movement.

Laxiriva Neutral is formulated with electrolytes (sodium chloride, sodium bicarbonate, and potassium chloride) in addition to macrogol 3350. The inclusion of electrolytes serves an important physiological purpose: as macrogol 3350 retains water in the intestinal lumen, there is a potential for a net exchange of electrolytes across the intestinal wall. By including electrolytes in the formulation at isotonic concentrations, Laxiriva Neutral ensures that there is virtually no net gain or loss of sodium, potassium, or water during its passage through the gut. This is particularly important when higher doses are used for bowel preparation before colonoscopy, where large volumes of fluid pass through the intestines. The electrolyte-balanced formulation helps maintain the body’s hydration and electrolyte homeostasis throughout the process.

Chronic constipation is one of the most common gastrointestinal complaints worldwide, affecting an estimated 10–15% of the global adult population according to the World Gastroenterology Organisation (WGO). It is characterized by infrequent bowel movements (typically fewer than three per week), hard or lumpy stools, straining during defecation, a sensation of incomplete evacuation, and a need for manual maneuvers to facilitate defecation. Chronic constipation can significantly impair quality of life, leading to abdominal discomfort, bloating, reduced appetite, and considerable psychological distress. It is more prevalent in women, the elderly, individuals with sedentary lifestyles, and those taking certain medications (particularly opioids, antidepressants, antacids containing calcium or aluminum, and iron supplements).

Clinical evidence supporting the use of macrogol-based laxatives for chronic constipation is robust. A Cochrane systematic review examining osmotic and stimulant laxatives for chronic constipation found that PEG-based products (including macrogol 3350) were superior to placebo and to lactulose (another osmotic laxative) in increasing stool frequency and improving stool consistency. Multiple randomized controlled trials have demonstrated that macrogol 3350 increases the number of weekly bowel movements, reduces straining, improves stool consistency according to the Bristol Stool Scale, and enhances patient-reported outcomes and satisfaction. International guidelines from the American Gastroenterological Association (AGA), the British Society of Gastroenterology (BSG), and the WGO all recommend osmotic laxatives including macrogol as first-line pharmacological treatment for chronic constipation when lifestyle modifications alone are insufficient.

In addition to its use for chronic constipation, Laxiriva Neutral is used for bowel preparation before colonoscopy and other diagnostic or surgical procedures that require a clean bowel. Effective bowel preparation is critical for the success of colonoscopy, as residual fecal matter can obscure the mucosal surface and reduce the detection rate of polyps and other lesions. When used for bowel preparation, Laxiriva Neutral is typically administered at higher doses over a shorter period (usually the day before the procedure), often as part of a split-dose regimen. The high-volume fluid intake combined with the osmotic effect of macrogol 3350 produces a thorough washout of the colonic contents, resulting in a clear field of view for the endoscopist.

What Should You Know Before Taking Laxiriva Neutral?

Contraindications

Laxiriva Neutral must not be used in certain clinical situations where the passage of large volumes of fluid through the gastrointestinal tract could be harmful. The primary contraindications include:

• Intestinal obstruction or perforation: Any known or suspected mechanical obstruction of the gastrointestinal tract (bowel obstruction) is an absolute contraindication. Using an osmotic laxative in the presence of obstruction could lead to dangerous distension of the bowel proximal to the blockage, increasing the risk of perforation, ischemia, or peritonitis. Similarly, if intestinal perforation has already occurred, the administration of any oral laxative is contraindicated.
• Severe inflammatory conditions of the intestinal tract: Laxiriva Neutral should not be used in patients with severe inflammatory bowel disease (IBD), including active ulcerative colitis, Crohn’s disease during an acute flare, or toxic megacolon. The increased fluid volume in the bowel lumen could exacerbate inflammation, increase the risk of perforation, and potentially worsen the clinical condition.
• Ileus: Paralytic ileus (a condition in which the normal peristaltic movements of the bowel are absent or severely impaired) is a contraindication because the medication relies on peristalsis to move intestinal contents forward. In the absence of functional bowel motility, fluid and macrogol would accumulate in the gut, potentially leading to distension, vomiting, and aspiration.
• Hypersensitivity: Patients with a known allergy to macrogol (polyethylene glycol) or any of the other excipients in the formulation should not use Laxiriva Neutral. Although allergic reactions to macrogol are rare, they have been reported and can include skin rash, urticaria, angioedema, and in very rare cases, anaphylaxis.

Warnings and Precautions

Before starting Laxiriva Neutral, discuss the following with your healthcare provider:

• Renal impairment: Although macrogol 3350 itself is not absorbed, the electrolyte components (sodium and potassium) could theoretically affect patients with significantly impaired kidney function. Patients with severe renal impairment may have difficulty excreting any absorbed electrolytes. Your doctor may want to monitor your kidney function and electrolyte levels during treatment, particularly if you are using higher doses for bowel preparation.
• Heart failure or cardiovascular disease: The sodium content in Laxiriva Neutral may be relevant for patients with congestive heart failure or other conditions requiring sodium restriction. Discuss with your doctor whether the sodium content of the formulation is clinically significant for your individual situation, particularly if you are using higher doses.
• Impaired gag reflex or tendency to aspirate: Patients who are debilitated, semi-conscious, or prone to aspiration should use Laxiriva Neutral with extreme caution, as there is a risk of regurgitation and aspiration of the solution. In such patients, administration should be supervised by healthcare professionals, and consideration should be given to nasogastric administration if necessary.
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency: There have been isolated reports of metabolic acidosis in patients with G6PD deficiency who used large volumes of PEG-based bowel preparations. While this is extremely rare, patients with known G6PD deficiency should inform their doctor before using Laxiriva Neutral.

Pregnancy and Breastfeeding

Constipation is extremely common during pregnancy, affecting up to 40% of pregnant women at some point during gestation. The causes are multifactorial and include elevated progesterone levels (which slow intestinal motility), physical compression of the bowel by the expanding uterus, reduced physical activity, and iron supplementation. Because macrogol 3350 is not absorbed from the gastrointestinal tract, it does not enter the systemic circulation and therefore cannot cross the placenta or reach the developing fetus. This makes macrogol-based laxatives one of the safer pharmacological options for managing constipation during pregnancy.

Clinical experience and limited observational data have not identified any harmful effects of macrogol 3350 on pregnancy outcomes. However, as with all medications during pregnancy, Laxiriva Neutral should only be used when the expected benefit to the mother outweighs any potential risk, and always under the supervision of a healthcare provider. Before resorting to pharmacological treatment, pregnant women should try non-pharmacological approaches such as increasing dietary fiber, maintaining adequate fluid intake, and engaging in regular physical activity within the limits recommended by their obstetrician.

Similarly, because macrogol 3350 is not absorbed systemically, it is not expected to be excreted in breast milk. Macrogol-based laxatives are generally considered compatible with breastfeeding. Nevertheless, it is advisable to discuss any medication use with your doctor or midwife while breastfeeding.

Children and Adolescents

Macrogol-based laxatives are widely used in pediatric medicine for the treatment of childhood constipation and fecal impaction. However, Laxiriva Neutral is specifically formulated and dosed for adult use. Pediatric formulations of macrogol are available in different concentrations and dosage forms that are specifically designed for children. If your child has constipation, consult a pediatrician who can prescribe the appropriate macrogol formulation and dosage based on the child’s age, weight, and clinical situation. Do not administer adult-dose sachets to children without medical guidance, as the electrolyte content and macrogol dose may not be appropriate.

Driving and Operating Machinery

Laxiriva Neutral has no known effect on the ability to drive or operate machinery. Because macrogol 3350 is not absorbed and does not affect the central nervous system, it does not cause drowsiness, dizziness, or any cognitive impairment. Patients can continue their normal daily activities while using this medication.

How Does Laxiriva Neutral Interact with Other Drugs?

Unlike many pharmaceutical agents that interact through enzymatic inhibition, induction, or protein binding, the interaction potential of Laxiriva Neutral is primarily related to its physical effects on gastrointestinal transit and absorption. Macrogol 3350 is an inert polymer that is not absorbed from the gut and does not undergo any metabolic transformation. It is not metabolized by cytochrome P450 (CYP) enzymes and does not bind to plasma proteins. Therefore, Laxiriva Neutral does not have the classic pharmacokinetic drug interactions that are associated with many other medications.

However, there is an important practical consideration: the osmotic action of macrogol 3350 increases the water content and volume of intestinal contents, and the resulting increased peristalsis can accelerate gastrointestinal transit time. This means that other medications taken around the same time as Laxiriva Neutral may spend less time in contact with the absorptive surface of the small intestine, potentially reducing their absorption and bioavailability. This effect is particularly relevant for:

As a general clinical recommendation, patients should take other oral medications at least 1 hour before or 1–2 hours after taking Laxiriva Neutral. This separation provides sufficient time for the co-administered medication to be absorbed from the gastrointestinal tract before the osmotic effects of macrogol 3350 begin to alter intestinal transit. For medications with a particularly narrow therapeutic index (where small changes in blood levels can have significant clinical consequences), even greater separation may be advisable, and your doctor should be consulted.

It is worth noting that the interaction risk is greatest when Laxiriva Neutral is used at higher doses for bowel preparation, as the large volume of fluid and the resulting rapid intestinal transit virtually guarantee that any co-administered oral medication will not be properly absorbed. For this reason, patients undergoing bowel preparation should discuss all their regular medications with their doctor, who may advise temporary dose adjustments, alternative administration routes (such as intravenous or transdermal), or specific timing strategies to ensure that essential medications maintain their therapeutic effect throughout the preparation period.

Laxiriva Neutral may also interact with other laxatives. Concurrent use of multiple laxative agents (particularly stimulant laxatives such as senna or bisacodyl) with osmotic laxatives can increase the risk of diarrhea, dehydration, and electrolyte disturbances. Combining different types of laxatives should only be done under medical supervision.

What Is the Correct Dosage of Laxiriva Neutral?

Laxiriva Neutral should always be used exactly as your doctor or pharmacist has instructed. The powder in each sachet must be dissolved in the appropriate volume of water before consumption. Do not take the powder dry, as it must be fully dissolved to work properly and to avoid the risk of choking or esophageal obstruction. Each sachet should be dissolved in approximately 125 mL (about half a glass) of water. Stir the solution until the powder is completely dissolved, which usually takes 2–3 minutes, and then drink the solution promptly.

Adults – Chronic Constipation

For chronic constipation, the starting dose is usually 1 sachet taken once or twice daily. Your doctor may increase the dose to up to 3 sachets per day depending on your response. The dose should be adjusted to produce regular, comfortable bowel movements – typically one or two soft stools per day. Once a regular bowel habit has been established, the dose can often be reduced to the minimum effective dose. Treatment for constipation usually lasts for up to 2 weeks, but your doctor may recommend a longer course if clinically indicated, particularly for patients with chronic or recurring constipation.

For the treatment of fecal impaction (a condition in which hardened stool becomes lodged in the rectum or colon and cannot be passed), higher doses may be prescribed. The typical regimen involves dissolving 8 sachets in 1 liter of water and drinking the solution over a period of 6 hours. This regimen is usually continued for up to 3 consecutive days. Treatment of fecal impaction should always be supervised by a healthcare professional, and patients should be monitored for signs of dehydration or electrolyte imbalance.

Adults – Bowel Preparation

When Laxiriva Neutral is used for bowel preparation before colonoscopy or other diagnostic procedures, the dosing regimen is significantly different from that used for constipation. Bowel preparation requires the ingestion of large volumes of macrogol solution to achieve complete colonic cleansing. The specific regimen varies depending on the product formulation, the type of procedure, and institutional protocols. Your doctor or endoscopy unit will provide detailed instructions specific to your preparation.

A common approach is the split-dose regimen, in which half the preparation is taken the evening before the procedure and the other half on the morning of the procedure (typically 4–6 hours before the scheduled time). This split-dose approach has been shown in clinical studies to produce superior bowel cleanliness compared with same-evening-only preparations, and it is now recommended by the European Society of Gastrointestinal Endoscopy (ESGE) and other professional societies as the preferred method of bowel preparation.

Children

Laxiriva Neutral is formulated for adult use. Pediatric dosing of macrogol-based products differs significantly, and children should only receive macrogol preparations specifically formulated and licensed for their age group. For childhood constipation, which is very common (affecting approximately 5–30% of children worldwide depending on the definition used), consult a pediatrician who will prescribe the appropriate product and dose. The National Institute for Health and Care Excellence (NICE) guidelines recommend macrogol as the first-line pharmacological treatment for childhood constipation, but the dose must be carefully calculated based on the child’s age and weight.

Elderly Patients

No dose adjustment is generally required for elderly patients when using Laxiriva Neutral for constipation. However, elderly patients may be more susceptible to dehydration and electrolyte disturbances, particularly if they have impaired renal function or are taking diuretics. Healthcare providers should ensure that elderly patients maintain adequate fluid intake during treatment and may wish to monitor renal function and electrolytes, particularly during higher-dose bowel preparation regimens. Starting at the lower end of the dosing range and titrating upward as needed is a prudent approach in elderly patients.

Missed Dose

If you forget to take a dose of Laxiriva Neutral, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed dose. If you are using Laxiriva Neutral for bowel preparation before a procedure, follow the specific instructions provided by your endoscopy unit carefully, as the timing of doses is critical for adequate preparation.

Overdose

Taking more Laxiriva Neutral than prescribed can lead to diarrhea, abdominal pain, nausea, and vomiting. In severe cases, particularly in elderly patients or those with renal impairment, overdose could lead to dehydration and electrolyte disturbances (such as low potassium, low sodium, or metabolic acidosis). If you have taken significantly more than the recommended dose and are experiencing symptoms, contact your doctor or local poison control center. Treatment of overdose is supportive: ensure adequate fluid and electrolyte replacement, and discontinue the macrogol until symptoms resolve.

How to Prepare the Solution

Proper preparation of the Laxiriva Neutral solution is important for both efficacy and palatability:

1. Open the sachet: Tear open one sachet along the perforated line.
2. Add water: Pour the contents into a glass and add approximately 125 mL (about half a standard glass) of water. Use room-temperature or cold water; do not use hot or carbonated beverages.
3. Stir thoroughly: Stir the mixture for 2–3 minutes until the powder is completely dissolved. The solution should be clear or very slightly hazy. If any undissolved particles remain, continue stirring.
4. Drink promptly: Once prepared, drink the solution within a short period. The prepared solution can be kept in the refrigerator for up to 6 hours if needed, but it is best consumed fresh.
5. Drink additional fluids: After taking Laxiriva Neutral, drink additional water or clear fluids throughout the day to maintain adequate hydration. This is essential for the medication to work effectively.

What Are the Side Effects of Laxiriva Neutral?

Like all medicines, Laxiriva Neutral can cause side effects, although not everyone who takes it will experience them. The majority of reported adverse effects are related to the gastrointestinal tract and are a direct consequence of the medication’s mechanism of action (increasing fluid volume and intestinal motility). These effects are generally mild, self-limiting, and often improve as the body adjusts to the medication or when the dose is reduced.

The safety profile of macrogol 3350 has been extensively characterized through clinical trials, post-marketing surveillance, and decades of widespread clinical use worldwide. Because macrogol 3350 is not absorbed from the gastrointestinal tract and does not undergo metabolic transformation, systemic side effects are extremely rare. The overall safety profile of Laxiriva Neutral is favorable compared with many other laxative classes, particularly stimulant laxatives, which carry risks of electrolyte depletion, cathartic colon, and dependency with long-term use.

Gastrointestinal side effects (abdominal pain, bloating, nausea, and diarrhea) are the most commonly reported adverse effects and are directly related to the medication’s mechanism of action. These symptoms are usually mild and tend to resolve within the first few days of treatment as the bowel adjusts to the increased fluid volume. If diarrhea occurs, it is usually a sign that the dose is too high, and reducing the dose typically resolves the problem. If you experience persistent or severe diarrhea, stop taking Laxiriva Neutral and consult your doctor, as prolonged diarrhea can lead to dehydration and electrolyte imbalances.

Electrolyte disturbances are uncommon with standard doses used for constipation but can occur more frequently with higher doses used for bowel preparation or fecal impaction. The electrolyte-balanced formulation of Laxiriva Neutral is specifically designed to minimize this risk. However, patients who are elderly, have renal impairment, are taking diuretics, or are on medications that affect electrolyte balance should be monitored. Symptoms of electrolyte imbalance may include muscle weakness, muscle cramps, irregular heartbeat, confusion, or excessive fatigue.

Allergic reactions to macrogol (polyethylene glycol) are rare but have been documented in medical literature. Cross-reactivity can occur with other PEG-containing products, including certain medications, cosmetics, and medical devices. If you experience symptoms such as skin rash, hives, swelling of the face or throat, difficulty breathing, or a feeling of faintness after taking Laxiriva Neutral, stop taking the medication and seek immediate medical attention.

How Should You Store Laxiriva Neutral?

Proper storage of Laxiriva Neutral ensures that the product remains effective and safe throughout its shelf life. As a powder formulation, Laxiriva Neutral is relatively stable when stored under appropriate conditions, but exposure to moisture can cause the powder to clump or partially dissolve within the sachet, potentially affecting the accuracy of dosing and the ease of preparation.

• Temperature: Store at room temperature, not exceeding 25°C (77°F). Do not freeze the product. While brief exposure to higher temperatures during transport is unlikely to affect the product, avoid prolonged storage in hot environments such as cars in summer or near radiators.
• Moisture protection: Keep the sachets in their original packaging until ready to use. The powder is hygroscopic (it absorbs moisture from the air), so once a sachet is opened, the contents should be dissolved in water and consumed promptly. Do not store opened sachets.
• Light: No special precautions regarding light exposure are required for this product.
• Prepared solution: Once the powder has been dissolved in water, the solution should ideally be consumed immediately. If necessary, the prepared solution can be covered and stored in a refrigerator (2–8°C) for up to 6 hours. Discard any prepared solution that has been left at room temperature for more than 6 hours or refrigerated for more than 24 hours.
• Keep out of reach of children: Store Laxiriva Neutral in a location that is inaccessible to children. While macrogol 3350 is not toxic, accidental ingestion by a child could cause diarrhea and discomfort.
• Expiration date: Do not use Laxiriva Neutral after the expiration date printed on the sachet and outer packaging. The expiration date refers to the last day of the stated month.
• Disposal: Do not dispose of unused sachets in household waste or wastewater. Return unused or expired sachets to your pharmacy for proper disposal in accordance with local regulations.

When traveling, keep sachets in their original packaging in a cool, dry place in your luggage. The powder formulation is convenient for travel, as individual sachets are lightweight, do not require refrigeration, and can be dissolved in water at your destination. If traveling to areas with unreliable water quality, use bottled water to prepare the solution.

What Does Laxiriva Neutral Contain?

Understanding the composition of Laxiriva Neutral is important for patients with allergies, dietary restrictions, or specific medical conditions that require careful monitoring of sodium or potassium intake.

Active Ingredient

The active substance is macrogol 3350 (also known as polyethylene glycol 3350 or PEG 3350). Each sachet contains 13.125 g of macrogol 3350. Macrogol 3350 is a linear polymer of ethylene oxide with an average molecular weight of 3350 daltons. It is a white to off-white powder that is freely soluble in water. The number “3350” refers to the average molecular weight of the polymer, which determines its osmotic properties and viscosity in solution. This molecular weight is optimal for use as an osmotic laxative: large enough to not be absorbed from the gastrointestinal tract, but small enough to dissolve readily in water and form a palatable solution.

Electrolytes

What Laxiriva Neutral Does Not Contain

The “Neutral” formulation is notable for what it does not contain: no artificial flavors, no sweeteners (such as aspartame or saccharin), no colors, and no preservatives. This makes it suitable for patients who are sensitive to artificial additives or who prefer an unflavored preparation. The formulation is also free from gluten, lactose, sucrose, and gelatin, making it appropriate for patients with celiac disease, lactose intolerance, or specific dietary requirements.

Sodium Content

Patients on a sodium-restricted diet should be aware of the sodium content of Laxiriva Neutral. Each sachet contains sodium from both sodium chloride and sodium bicarbonate. When using standard doses for constipation (1–3 sachets per day), the sodium load is generally modest and clinically insignificant for most patients. However, when higher doses are used for bowel preparation or fecal impaction, the cumulative sodium intake can be substantial. Patients with heart failure, severe kidney disease, or other conditions requiring strict sodium restriction should discuss this with their doctor before using Laxiriva Neutral.

Appearance and Packaging

Laxiriva Neutral is supplied as a white to off-white powder in individual unit-dose sachets. Each sachet is sealed in a moisture-resistant foil to protect the hygroscopic powder. Sachets are typically available in boxes containing 20, 30, 50, or 100 sachets. Not all pack sizes may be available in every country.